Pembrolizumab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Conditions:   Lymphocyte-Rich Classical Hodgkin Lymphoma;   Recurrent Lymphocyte-Depleted Classical Hodgkin Lymphoma;   Recurrent Mixed Cellularity Classical Hodgkin Lymphoma;   Recurrent Nodular Sclerosis Classical Hodgkin Lymphoma;   Refractory Lymphocyte-Depleted Classical Hodgkin Lymphoma;   Refractory Mixed Cellularity Classical Hodgkin Lymphoma;   Refractory Nodular Sclerosis Classical Hodgkin Lymphoma
Interventions:   Drug: Carboplatin;   Drug: Etoposide;   Drug: Ifosfamide;   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab
Sponsors:   Northwestern University;   Merck Sharp & Dohme Corp.;   National Cancer Institute (NCI)
Not yet recruiting - verified March 2017

http://ift.tt/2miRITW